Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ524524,5-0,19
KB828830-2,19
PKN91,4491,54-2,72
Msft136,18136,29-0,03
Nokia4,5634,57-1,53
IBM142,13143,08-0,22
Daimler AG46,97546,985-2,22
PFE36,8336,90,00
17.09.2019 14:10:54
Indexy online
AD Index online
select
AD Index online
 

  • 16.09.2019
Gilead Sciences (GILD.O, NASDAQ Cons)
Závěr k 16.9.2019 Změna (%) Změna (USD) Objem obchodů (ks)
65,88 -0,96 -0,64 4 644 135
Premarket17.09.2019 13:43:19
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
- 65,90 66,47 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 17.09.2019
Popis společnosti
Obecné informace
Název společnostiGilead Sciences, Inc.
TickerGILD
Kmenové akcie:Ordinary Shares
RICGILD.O
ISINUS3755581036
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.06.2019
Počet zaměstnanců k 31.01.2019 11 000
Akcie v oběhu k 30.07.20191 266 455 481
Počet akcionářů k 31.12.2018 375
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice333 LAKESIDE DR
MěstoFOSTER CITY
PSČ94404
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 505 743 000
Fax16505789264

Business Summary: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
Financial Summary: BRIEF: For the six months ended 30 June 2019, Gilead Sciences, Inc. revenues increased 2% to $10.97B. Net income before extraordinary items increased 15% to $3.86B. Revenues reflect United States-Biktarvy segment increase from $218M to $1.76B, United States-Sofosbuvir/Velpatasvir segment increase of 67% to $449M. Net income benefited from Other Non Rec. I/E - Non Business Acti increase from $19M (expense) to $254M (income), Other income (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSBiological Product (except Diagnostic) Manufacturing
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 17.09.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerDaniel O'Day5501.03.201901.03.2019
Chief Financial Officer, Executive Vice PresidentRobin Washington5623.01.201405.05.2008
Executive Vice President, Chief Compliance Officer, General CounselBrett Pletcher5101.01.2005
Executive Vice President of Human ResourcesJyoti Mehra-05.08.201905.08.2019
Executive Vice President - Corporate Development and StrategyAndrew Dickinson-04.06.201804.06.2018
Chief Patient OfficerGregg Alton5328.07.2005
Chief Commercial OfficerJohanna Mercier-29.05.201929.05.2019